ERBB2 and neoplasm: Secondly, we aimed to adjust for demographic and tumour-related factors and benchmark long-term survival rates in HER2-positive early-stage breast cancer patients between Stockholm-Gotland and Skane, Sweden's two largest healthcare regions.